Background. Positron emission tomography-computed tomography (PET/CT) with 18F-fluorocholine (FCH) is routinely performed in patients with prostate cancer. In this clinical context, foci of FCH uptake in the head or in the neck were considered as incidentalomas, except for those suggestive of multiple bone metastases.
Results. In 8 patients the incidental focus corresponded to a benign tumour. The standard of truth was histology in two cases, correlative imaging with MRI in four cases, 99mTc-SestaMIBI scintigraphy, ultrasonography and biochemistry in one case and biochemistry including PTH assay in one case. The final diagnosis of benign tumours consisted in 3 pituitary adenomas, 2 meningiomas, 2 hyperfunctioning parathyroid glands and 1 thyroid adenoma. Malignancy was proven histologically in 2 other patients: 1 papillary carcinoma of the thyroid and 1 cerebellar metastasis.
Conclusions. To the best of our knowledge, FCH uptake by pituitary adenomas or hyperfunctioning parathyroid glands has never been described previously. We thus discuss whether there might be a future indication for FCH PET/ CT when one such tumour is already known or suspected: to detect a residual or recurrent pituitary adenoma after surgery, to guide surgery or radiotherapy of a meningioma or to localise a hyperfunctioning parathyroid gland. In these potential indications, comparative studies with reference PET tracers or with 99mTc-sestaMIBI in case of hyperparathyroidism could be undertaken.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Balogova S Kobetz A Huchet V Michaud L Kerrou K Paycha F et al. Evolution of the prescription of nuclear medicine examinations in prostate cancer since the registration of fluorocholine (18F): a two-year survey at hospital Tenon. Med Nucl 2012; 36: 363-70.
2. Cimitan M Bortolus R Morassut S Canzonieri V Garbeglio A Baresic T et al. [18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33: 1387-98.
3. Treglia G Giovannini E Di Franco D Calcagni ML Rufini V Picchio M et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med 2012; 26: 451-61.
4. Hodolič M Fettich J Cimitan M Kragelj B Goldsmith SJ. Unusual F-18 choline uptake in penile metastasis from prostate cancer. Clin Nucl Med 2012; 37: e89-90.
5. Schillaci O Calabria F Tavolozza M Cicciò C Carlani M Caracciolo CR et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun 2010; 31: 39-45.
6. Balogova S Nataf V Gutman F Huchet V Kerrou K Pascal O et al. Biological recurrence of prostate cancer: Interest of whole-body fluorocholine (18F) PET/CT. Med Nucl 2010; 34: 540-5.
7. Mertens K Ham H Deblaere K Kalala JP Van den Broecke C Slaets D et al. Distribution patterns of 18F-labelled fluoromethylcholine in normal structures and tumors of the head: a PET/MRI evaluation. Clin Nucl Med 2012; 37: e196-203.
8. Jeong SY Lee SW Lee HJ Kang S Seo JH Chun KA et al. Incidental pituitary uptake on whole-body 18F-FDG PET/CT: a multicentre study. Eur J Nucl Med Mol Imaging 2010; 37: 2334-43.
9. Hyun SH Choi JY Lee KH Choe YS Kim BT. Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria. J Nucl Med 2011; 52: 547-50.
10. De Souza B Brunetti A Fulham MJ Brooks RA DeMichele D Cook P et al. Pituitary microadenomas: a PET study. Radiology 1990; 177: 39-44.
11. Daemen BJ Zwertbroek R Elsinga PH Paans AM Doorenbos H Vaalburg W. PET studies with L-[1-11C]tyrosine L-[methyl-11C]methionine and 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment. Eur J Nucl Med 1991; 18: 453-60.
12. Bergström M Muhr C Lundberg PO Långström B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 1991; 32: 10-5.
13. Tang BN Levivier M Heureux M Wikler D Massager N Devriendt D et al. 11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas. Eur J Nucl Med Mol Imaging 2006; 33: 169-78.
14. Muhr C. Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology 2006; 83: 205-10.
15. Naswa N Das CJ Sharma P Karunanithi S Bal C Kumar R. Ectopic pituitary adenoma with empty sella in the setting of MEN-1 syndrome detection with 68Ga-DOTANOC PET/CT. Jpn J Radiol 2012; 30: 783-6.
16. Veit JA Boehm B Luster M Scheuerle A Rotter N Rettinger G et al. Detection of paranasal ectopic adrenocorticotropic hormone-secreting pituitary adenoma by Ga-68-DOTANOC positron-emission tomographycomputed tomography. Laryngoscope 2013; 123: 1132-5.
17. Mertens K Bolcaen J Ham H Deblaere K Van den Broecke C Boterberg T et al. The optimal timing for imaging brain tumours and other brain lesions with 18F-labelled fluoromethylcholine: a dynamic positron emission tomography study. Nucl Med Commun 2012; 33: 954-9.
18. Giovacchini G Fallanca F Landoni C Gianolli L Picozzi P Attuati L et al. C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience. Clin Nucl Med 2009; 34: 7-10.
19. Liu RS Chang CP Guo WY Pan DH Ho DM Chang CW et al. 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery. J Nucl Med 2010; 51: 883-91.
20. Xiangsong Z Xingchong S Chang Y Xiaoyan W Zhifeng C. 13N-NH3 versus F-18 FDG in detection of intracranial meningioma: initial report. Clin Nucl Med 2011; 36: 1003-6.
21. Astner ST Dobrei-Ciuchendea M Essler M Bundschuh RA Sai H Schwaiger M et al. Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys 2008; 72: 1161-7.
22. Rutten I Cabay JE Withofs N Lemaire C Aerts J Baart V et al. PET/CT of skull base meningiomas using 2-18F-fluoro-L-tyrosine: initial report. J Nucl Med 2007; 48: 720-5.
23. González-Forero M Prieto E Domínguez I Vigil C Peñuelas I Arbizu J. Dual time point 18F-FDOPA PET as a tool for characterizing brain tumors. Rev Esp Med Nucl 2011; 30: 88-93.
24. Afshar-Oromieh A Giesel FL Linhart HG Haberkorn U Haufe S Combs SE et al.. Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging 2012; 39: 1409-15.
25. Mapelli P Busnardo E Magnani P Freschi M Picchio M Gianolli L et al. Incidental finding of parathyroid adenoma with 11C-choline PET/CT. Clin Nucl Med 2012; 37: 593-5.
26. Mendoza PL Ongkeko EE Santiago JF. Silent parathyroid adenoma mistakenly interpreted on FDG-PET as thyroid cancer metastasis in a patient with elevated thyroglobulin and negative I-131 whole body scan and removed by radioguided minimally invasive surgery. Clin Nucl Med 2008; 33: 23-5.
27. Kim MK Kim GS Kim SY Baek KH Kang MI Lee KW et al. F-18 FDG-avid intrathyroidal parathyroid adenoma mimicking follicular neoplasm. Clin Nucl Med 2009; 34: 178-9.
28. Evangelista L Sorgato N Torresan F Boschin IM Pennelli G Saladini G et al. FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series. World J Clin Oncol 2011; 2: 348-54.
29. Sisson JC Thompson NW Ackerman RJ Wahl RL. Use of 2-[F-18]-fluoro-2- deoxy-D-glucose PET to locate parathyroid adenomas in primary hyperparathyroidism. Radiology 1994; 192: 280.
30. Melon P Luxen A Hamoir E Meurisse M. Fluorine-18-fluorodeoxyglucose positron emission tomography for preoperative parathyroid imaging in primary hyperparathyroidism. Eur J Nucl Med 1995; 22: 556-8.
31. Neumann DR Esselstyn CB Maclntyre WJ Go RT Obuchowski NA Chen EQ Licata AA. Comparison of FDG-PET and sestamibi-SPECT in primary hyperparathyroidism. J Nucl Med 1996; 37: 1809-15.
32. Caldarella C Treglia G Isgrò MA Giordano A. Diagnostic performance of positron emission tomography using 11C-methionine in patients with suspected parathyroid adenoma: a meta-analysis. Endocrine 2013; 43: 78-83.
33. García Vicente AM Núñez García A Soriano Castrejón AM Jiménez Londoño GA Cordero García JM Palomar Muñoz A. Pitfalls with 18F-choline PET/CT in patients with prostate cancer. Rev Esp Med Nucl Imagen Mol 2013; 32: 37-9.
34. Treglia G Giovannini E Mirk P Di Franco D Oragano L Bertagna F. A thyroid Incidentaloma detected by 18F-Choline PET/CT. Clin Nucl Med 2014; 39(4): e267-9..
35. Yang Z Shi W Zhu B Hu S Zhang Y Wang M et al. Prevalence and risk of cancer of thyroid incidentaloma identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. J Otolaryngol Head Neck Surg 2012; 41: 327-33.
36. Bertagna F Treglia G Piccardo A Giovannini E Bosio G Biasiotto G et al. F18-FDG-PET/CT thyroid incidentalomas: a wide retrospective analysis in three Italian centres on the significance of focal uptake and SUV value. Endocrine 2013; 43: 678-85.
37. Soelberg KK Bonnema SJ Brix TH Hegedüs L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid 2012; 22: 918-25.
38. Wu HB Wang QS Wang MF Li HS. Utility of ¹¹C-choline imaging as a supplement to F-18 FDG PET imaging for detection of thyroid carcinoma. Clin Nucl Med 2011; 36: 91-5.
39. Hodolic M Michaud L Huchet V Balogova S Nataf V Kerrou K et al. Consequence of the introduction of routine FCH PET/CT imaging in patients with prostate cancer: a dual centre survey. Radiol Oncol 2014; 48: 20-8.